.png){kind=icon}
返回
R
Rodrigo E. Mendes
JMI Laboratories
65H指数
551论文数
1.3W被引数
收录论文 200
发表时间
.png){kind=icon}
Characterization of isolates from two phase 3 uncomplicated urinary tract infection trials (EAGLE-2 and EAGLE-3) that show an apparent ≥4-fold increase in gepotidacin MIC between baseline and post-baseline visits来自两项III期非复杂性尿路感染试验（EAGLE-2和EAGLE-3）的分离株特征，这些分离株在基线与基线后访视期间表现出≥4倍的增加的gepotidacin MIC.png)
OAAI
OAAI.png){kind=icon}
分享.png){kind=icon}
收藏Activity of cefiderocol against Pseudomonas aeruginosa from the USA and Europe (2020-2023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed β-lactam/β-lactamase inhibitor combinations: results from the SENTRY antimicrobial surveillance programcefiderocol对来自美国和欧洲 (2020-2023) 具有难以治疗的耐药表型的铜绿假单胞菌的活性，包括对最近开发的 β-内酰胺/β-内酰胺酶抑制剂组合不敏感的那些: SENTRY抗菌药物监测计划的结果
PREAI
分享收藏In vitro activity of SPR206 and comparator agents against Pseudomonas aeruginosa, Acinetobacter species, and Enterobacterales responsible for infection in United States, European, Israeli, and Turkish hospitalsSPR206及对照药物在体外对导致美国、欧洲、以色列和土耳其医院感染的铜绿假单胞菌（Pseudomonas aeruginosa）、不动杆菌属（Acinetobacter species）和肠杆菌科（Enterobacterales）的活性研究。OAAI
OAAI分享收藏Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5 years of surveillance prior to approval for clinical use (2019-2023)Sader, H.S.; Kimbrough, J.H.; Winkler, M.L.; Castanheira, M.; Mendes, R.E. 阿兹treonam/阿维巴坦对欧洲医疗中心肠杆菌科细菌的活性：临床使用批准前5年（2019–2023）的监测总结。J. Antimicrob. Chemother. 2025, 80, 2070–2079. [Google Scholar] [CrossRef]OAAI
OAAI分享收藏Characterization of Enterobacter cloacae and Citrobacter freundii Species Complex Isolates with Decreased Susceptibility to Cephalosporins from United States Hospitals and Activity of Aztreonam-Avibactam and Comparator Agents (2019-2023)肠杆菌属阴沟肠杆菌和柠檬酸杆菌属弗氏柠檬酸杆菌种复合群分离株对头孢菌素类敏感性降低的表征及阿佐环酰胺-维巴坦和他感剂的作用（2019-2023）.png)
ANTIBIOTICS-BASELOAAI
ANTIBIOTICS-BASELIF4.6
OAAI分享收藏In vitro activity assessment of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp., including β-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitals头孢地洛尔对肠杆菌，铜绿假单胞菌和不动杆菌属的体外活性评估，包括对 β-内酰胺不敏感的分子特征分离株，2020年美国和欧洲医院的2021年收集
OAAI
OAAI分享收藏